American Journal of Cancer

, Volume 3, Issue 6, pp 349–368 | Cite as

Hepatocellular Carcinoma

New Strategies to Improve Prognosis
  • Laurie Blendis
  • Morris Sherman
Review Article
  • 10 Downloads

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most patients still present late in the course of the disease so that curative therapy is rarely possible. Strategies developed to improve the prognosis include primary prevention, directed at the underlying liver diseases, secondary prevention by cancer surveillance and early intervention, and more effective therapies. Only childhood vaccination against hepatitis B (HBV) infection has been clearly documented to reduce the incidence of HCC. Eradication of the hepatitis B and C viruses by interferon in noncirrhotic patients may reduce the incidence of HCC. Removal of iron by phlebotomy in noncirrhotic patients with genetic hemochromatosis will largely prevent HCC. Many physicians offer secondary prevention by surveillance and early intervention involving repeated abdominal ultrasound and serial serum α-fetoprotein estimations in order to identify early malignant lesions, but such strategies have yet to be proven to reduce mortality from HCC. Nonetheless, early detection would seem to offer a greater chance for application of potentially curative therapy. Different surveillance strategies may be necessary in different patient groups. For example, in chronic hepatitis C the increased risk of HCC seems to be confined to patients with established cirrhosis, whereas even noncirrhotic patients with HBV have a substantially increased risk of HCC.

In high-risk patients, such as those with cirrhosis following chronic viral hepatitis, several factors can be identified which appear to confer additional risk. Examples are hepatocyte dysplasia found on biopsy, or non-neoplastic vascular nodules on computed tomography scanning. The management of such patients needs urgent resolution.

Potentially curative treatment options include resection, liver transplantation, and alcohol injection or radiofrequency ablation. Resection in ideal candidates may provide up to 60% survival at 5 years. Liver transplantation may result in a 5-year survival of up to 70%. However, the shortage of organ donors means that tumor progression while on the waiting list will disqualify some patients, while others will die before an organ becomes available. Local ablation has been reported to be as effective as resection and is applicable to a larger proportion of patients.

Of the palliative forms of therapy only chemoembolization has been shown to provide a significant improvement in life-span, although other forms of adjuvant and palliative therapy are under investigation.

Keywords

Liver Transplantation Tace Cirrhotic Patient Percutaneous Ethanol Injection Dysplastic Nodule 

Notes

Acknowledgment

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33–64PubMedCrossRefGoogle Scholar
  2. 2.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421–30PubMedCrossRefGoogle Scholar
  3. 3.
    Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(5 Suppl. 1): S5–16PubMedCrossRefGoogle Scholar
  4. 4.
    Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650–5PubMedCrossRefGoogle Scholar
  5. 5.
    Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK, 1979–94. Lancet 1997 Oct 18; 350: 1142–3Google Scholar
  6. 6.
    Irvine HDV, Goldberg D, Hole DJ, et al. Trends in primary liver cancer. Lancet 1998 Jan 17; 351: 215–6Google Scholar
  7. 7.
    Deuffic S, Poynard T, Buffat L, et al. Trends in primary liver cancer. Lancet 1998 Jan 17; 351: 214–5Google Scholar
  8. 8.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 Mar 11; 340: 745–50Google Scholar
  9. 9.
    Di Bisceglie AM, Carithers RL, Gores GJ. Hepatocellular carcinoma. Hepatology 1998 Oct; 28(4): 1161–5Google Scholar
  10. 10.
    Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 918–28PubMedCrossRefGoogle Scholar
  11. 11.
    Yuen M-F, Cheng C-C, Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330–3PubMedCrossRefGoogle Scholar
  12. 12.
    Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus; a prospective study of 22,700 men in Taiwan. Lancet 1981; II: 1129–33CrossRefGoogle Scholar
  13. 13.
    Beasley RP. Hepatitis B virus the major etiology of hepatocellular carcinoma. Cancer 1988; 60: 1942–56CrossRefGoogle Scholar
  14. 14.
    Sakuma K, Saitoh N, Kasai MM, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988; 8: 1642–6PubMedCrossRefGoogle Scholar
  15. 15.
    Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294–8PubMedCrossRefGoogle Scholar
  16. 16.
    Kew MC. Hepatocellular carcinoma with and without cirrhosis. Gastroenterology 1989; 97: 136–9PubMedGoogle Scholar
  17. 17.
    Choo Q-L, Kuo G, Welner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 1989; 244: 359–62PubMedCrossRefGoogle Scholar
  18. 18.
    Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; II: 1004–6CrossRefGoogle Scholar
  19. 19.
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–5PubMedCrossRefGoogle Scholar
  20. 20.
    Wada I, Hara T, Kajihara S, et al. Population-based study of hepatitis C virus infection and hepatocellular carcinoma in Western Japan. Hepatol Res 2002; 23: 18–24PubMedCrossRefGoogle Scholar
  21. 21.
    Kew MC, Yu MC, Kedda M-A, et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in Southern African Blacks. Gastroenterology 1997; 112: 184–7PubMedCrossRefGoogle Scholar
  22. 22.
    Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994; 74: 2442–8PubMedCrossRefGoogle Scholar
  23. 23.
    Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179–83PubMedGoogle Scholar
  24. 24.
    Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl. 1): S87–96PubMedCrossRefGoogle Scholar
  25. 25.
    Columbo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675–8CrossRefGoogle Scholar
  26. 26.
    Brechot C, Nalpas B, Courouce A-M, et al. Evidence that hepatitis B has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med 1992; 306: 1384–7CrossRefGoogle Scholar
  27. 27.
    Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus (HBV) infections in hepatitis B surface antigen negative subjects: molecular basis, clinical impact and interplay with other pathogens. Hepatology 2001 Jul; 34: 194–203Google Scholar
  28. 28.
    Urashima T, Saigo K, Kobayashi S, et al. Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues. J Hepatol 1997; 26: 771–8PubMedCrossRefGoogle Scholar
  29. 29.
    Chung HT, Lai CL, Lok AS. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995; 22: 25–9PubMedGoogle Scholar
  30. 30.
    Yotsuyanagi H, Shintani Y, Moriya K, et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan. J Infect Dis 2000; 181: 1920–8PubMedCrossRefGoogle Scholar
  31. 31.
    Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace [editorial]. Hepatology 2001 Jul; 34: 204–6Google Scholar
  32. 32.
    Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5 Suppl. 1): S35–50PubMedCrossRefGoogle Scholar
  33. 33.
    Kuper H, Ye W, Broome U, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001 Aug; 34: 714–8Google Scholar
  34. 34.
    Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531–7PubMedCrossRefGoogle Scholar
  35. 35.
    Newberne PM, Butler WH. Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals: a review. Cancer Res 1969; 29: 236–50PubMedGoogle Scholar
  36. 36.
    Peers FG, Linscil CA. Dietary aflatoxins and liver cancer-a population based study in Kenya. Br J Cancer 1973; 27: 473–84PubMedCrossRefGoogle Scholar
  37. 37.
    Peers FG, Gilman GA, Linscil CA. Dietary aflatoxins and human liver cancer: a study in Swaziland. Int J Cancer 1976; 17: 167–76PubMedCrossRefGoogle Scholar
  38. 38.
    Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943–6PubMedCrossRefGoogle Scholar
  39. 39.
    Diallo MS, Sylla A, Sidibe K, et al. Prevalence of exposure to aflatoxin and hepatitis B and C viruses in Guinea, West Africa. Nat Toxins 1995; 3: 6–9PubMedCrossRefGoogle Scholar
  40. 40.
    Peers FG, Bosch X, Kaldor J, et al. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer 1987; 39: 545–53PubMedCrossRefGoogle Scholar
  41. 41.
    Yeh FS, Yu MC, Mo CC, et al. A serological case control study of primary hepatocellular carcinoma in Guangxi, China. Cancer Res 1985; 45: 872–3PubMedGoogle Scholar
  42. 42.
    Edwards CQ, Griffen LM, Goldard D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–62PubMedCrossRefGoogle Scholar
  43. 43.
    Bassett Ml, Halliday JW, Bryan S, et al. Screening for hemochromatosis. Ann N Y Acad sci 1988; 526: 274–89PubMedCrossRefGoogle Scholar
  44. 44.
    Velati C, Piperano A, Fargion S, et al. Prevalence of hemochromatosis in Italy: study of 1301 blood donors. Haematologia 1990; 75: 309–12Google Scholar
  45. 45.
    Feder JN, Gnirke A, Thomas W, et al. A novel MHC class1-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996; 13: 399–409PubMedCrossRefGoogle Scholar
  46. 46.
    Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001; 120: 718–25PubMedCrossRefGoogle Scholar
  47. 47.
    Francanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched controls patients with non-iron related chronic liver disease. Hepatology 2001; 33: 647–51CrossRefGoogle Scholar
  48. 48.
    Grodeuk VR, McLaren CE, MacPhail AP, et al. Association of iron overload in Africa and HCC and tuberculosis: Strachen’s 1929 thesis revisited. Blood 1996; 87: 3470–6Google Scholar
  49. 49.
    Brechot C. Hepatitis B (HBV) and hepatocellular carcinoma. J Hepatol 1987; 4: 269–79PubMedCrossRefGoogle Scholar
  50. 50.
    Fargion S, Fracanzani AL, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20: 1426–31PubMedCrossRefGoogle Scholar
  51. 51.
    Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998; 18: 67–75PubMedCrossRefGoogle Scholar
  52. 52.
    Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 1322–6PubMedCrossRefGoogle Scholar
  53. 53.
    Bonkovsky HL, Poh-Fitzpatrik M, Pimstone N, et al. Porphyria cutanea tarda; hepatitis C, HFE gene mutations in North America. Hepatology 1998; 27: 1661–9PubMedCrossRefGoogle Scholar
  54. 54.
    Elder GH. Alcohol intake and porphyria cutanea tarda. Clin Dermatol 1999; 17: 431–6PubMedCrossRefGoogle Scholar
  55. 55.
    Roberts AG, Wathley SD, Morgan TT, et al. Increased frequency of the haemochromatosis Cys282Ty mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321–3PubMedCrossRefGoogle Scholar
  56. 56.
    Sweeny GD. Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Clin Biochem 1986; 19Suppl. 1: 3–15CrossRefGoogle Scholar
  57. 57.
    Salata H, Cortes JM, de Salamanca RE, et al. Porphyria cutanea tarda and hepatocellular carcinoma. J Hepatol 1985; 1: 477–87PubMedCrossRefGoogle Scholar
  58. 58.
    Siersema PD, ten Kate FJW, Mulder PGH, et al. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 1992; 12: 56–61PubMedGoogle Scholar
  59. 59.
    Andant C, Puy H, Bograd C, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000; 32: 933–9PubMedCrossRefGoogle Scholar
  60. 60.
    Linet MS, Gridley G, Nyren O, et al. Primary liver cancer, other malignancies and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999; 149: 1010–5PubMedCrossRefGoogle Scholar
  61. 61.
    Berg NO, Eriksson S. Liver disease in adults with alphal-antitrypsin deficiency. N Engl J Med 1972; 287: 1264–7PubMedCrossRefGoogle Scholar
  62. 62.
    Eriksson S, Hagerstrand I. Cirrhosis and malignant hepatoma in alpha1-antitrypsin deficiency. Acta Med Scand 1974; 195: 451–8PubMedCrossRefGoogle Scholar
  63. 63.
    Sharp HL. Alpha1-antitrypsin: an ignored proteln in understanding liver disease. Semin Liver Dis 1982; 2: 314–28PubMedCrossRefGoogle Scholar
  64. 64.
    Berge T, Lundberg S. Cancer in Malmo 1958-1969: an autopsy study. Acta Pathol Microbiol Scand Suppl 1977; 260: 1–234PubMedGoogle Scholar
  65. 65.
    Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha1-antitrypsin deficiency. N Engl J Med 1986; 314: 736–9PubMedCrossRefGoogle Scholar
  66. 66.
    Propst T, Propst A, Dietze O, et al. Prevalence of hepatocellular carcinoma in alpha1-antitrypsin deficiency. J Hepatol 1994; 21: 1006–11PubMedCrossRefGoogle Scholar
  67. 67.
    Farinati F, Floreani A, De Maria N, et al. Hepatocellular carcinoma in primary biliary cirrhosis. J Hepatol 1994; 21: 315–6PubMedCrossRefGoogle Scholar
  68. 68.
    Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120: 1502–17PubMedCrossRefGoogle Scholar
  69. 69.
    Tavani A, Negri E, Parazzini F, et al. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993; 67(3): 635–7PubMedCrossRefGoogle Scholar
  70. 70.
    Kew MC, Song E, Mohammed A, et al. Contraceptive steroids as a risk factor for HCC. Hepatology 1990; 11: 298–302PubMedCrossRefGoogle Scholar
  71. 71.
    Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication [editorial]. J Hepatol 2000; 33: 1006–8PubMedCrossRefGoogle Scholar
  72. 72.
    McMahon BJ, Bulkow L, Harpster A, et al. Screening for HCC in Alaska natives infected with chronic hepatitis B: a 16 year population-based study. Hepatology 2000; 32: 842–6PubMedCrossRefGoogle Scholar
  73. 73.
    Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273–8PubMedCrossRefGoogle Scholar
  74. 74.
    Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422–4PubMedCrossRefGoogle Scholar
  75. 75.
    Anthony PP. Liver cell dysplasia: what is its significance? Hepatology 1987; 7: 394–5CrossRefGoogle Scholar
  76. 76.
    Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and capillarization in dysplastic nodules in cirrhosis. Am J Surg Pathol 1998; 22: 656–62PubMedCrossRefGoogle Scholar
  77. 77.
    Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30: 1174–8PubMedCrossRefGoogle Scholar
  78. 78.
    Frachon S, Gouysse G, Dumortier J, et al. Endothelial cell marker expression in dysplastic lesions of the liver. J Hepatol 2001; 34: 850–7PubMedCrossRefGoogle Scholar
  79. 79.
    Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995; 108: 812–7PubMedCrossRefGoogle Scholar
  80. 80.
    Ballardini G, Groff P, Zoli M, et al. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 1994; 20: 218–22PubMedCrossRefGoogle Scholar
  81. 81.
    Dutta U, Kench J, Byth K, et al. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum Pathol 1998; 29: 1279–84PubMedCrossRefGoogle Scholar
  82. 82.
    Borzio M, Trere D, Borzio F, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol 1998; 510: 96–101Google Scholar
  83. 83.
    Sherman M. Survelllance for hepatocellular carcinoma. Semin Oncol 2001; 28: 450–9PubMedCrossRefGoogle Scholar
  84. 84.
    Chen DS, Sung JL, Sheu JC, et al. Serum alpha fetoproteln in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404–9PubMedGoogle Scholar
  85. 85.
    Lok ASF, Lai C-I. Alpha-fetoproteln monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9: 110–5PubMedCrossRefGoogle Scholar
  86. 86.
    Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432–8PubMedGoogle Scholar
  87. 87.
    Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65–71PubMedCrossRefGoogle Scholar
  88. 88.
    Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoproteln in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61–6PubMedCrossRefGoogle Scholar
  89. 89.
    Kew MC, Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. Gastroenterology 1988; 94: 439–42PubMedGoogle Scholar
  90. 90.
    Trevisani F, D’Intino PE, Morscili-Labate AM, et al. Serum alpha-fetoproteln for diagnosis of hepatocellular carcinoma inpatients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570–5PubMedCrossRefGoogle Scholar
  91. 91.
    Sherman M. Alphafetoproteln: an obituary [editorial]. J Hepatol 2001; 34: 603–5PubMedCrossRefGoogle Scholar
  92. 92.
    Kumada T, Nakano S, Takeda I, et al. Clinical utility of Lens culinaris agglutininreactive alpha-fetoproteln in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999; 30: 125–30PubMedCrossRefGoogle Scholar
  93. 93.
    Sheu JC, Sung JL, Chen DS, et al. Growth rates of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259–66PubMedGoogle Scholar
  94. 94.
    Zoli M, Maglotti D, Bianchi G, et al. Efficacy of a survelllance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977–85PubMedCrossRefGoogle Scholar
  95. 95.
    McMahon BJ, Hoick P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759–68PubMedGoogle Scholar
  96. 96.
    Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000 Nov; 124(11): 1599–607PubMedGoogle Scholar
  97. 97.
    Llovet JM, Bustamente J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62–7PubMedCrossRefGoogle Scholar
  98. 98.
    Levy I, Grelg PD, Langer B, et al. Resection of hepatocellular carcinoma without preoperative tumour biopsy. Ann Surg 2001; 234: 206–9PubMedCrossRefGoogle Scholar
  99. 99.
    Takayasu K, Moriyama N, Muramatsu Y, et al. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. AJR Am J Roentgenol 1990; 155: 49–54PubMedGoogle Scholar
  100. 100.
    Murakami T, Kim T, Oi H, et al. Detectability of hypervascular hepatocellular carcinoma by arterial phase imaging of MRI and spiral CT. Acta Radiol 1995; 36: 372–6PubMedGoogle Scholar
  101. 101.
    Saini S, Stark DD, Hahn PF, et al. Ferrite particles: a supermagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 1987; 162: 217–22PubMedGoogle Scholar
  102. 102.
    Yamamoto H, Yamashita Y, Yoshimatsu S, et al. Hepatocellular carcinoma in cirrhotic livers: detection with enhanced and iron oxide-enhanced MR imaging. Radiology 1995; 195: 106–12PubMedGoogle Scholar
  103. 103.
    Hui A-M, Takayama T, Sano K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 2000; 33: 975–9PubMedCrossRefGoogle Scholar
  104. 104.
    Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018–22PubMedCrossRefGoogle Scholar
  105. 105.
    Sobin LH, Wittekind CH. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss Inc, 1997Google Scholar
  106. 106.
    Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998; 27: 1572–7PubMedCrossRefGoogle Scholar
  107. 107.
    Marsh JW, Dvorchik I, Bonham CA, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88: 538–43PubMedCrossRefGoogle Scholar
  108. 108.
    Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 27(5 Suppl. 1): S126–32CrossRefGoogle Scholar
  109. 109.
    Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma: Groupe d’etude et de traitment du carcinome hepatocellulaire. J Hepatol 1999; 31: 133–41PubMedCrossRefGoogle Scholar
  110. 110.
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329–38PubMedCrossRefGoogle Scholar
  111. 111.
    The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751–5CrossRefGoogle Scholar
  112. 112.
    Farinati F, Rinaldi M, Gianni S, et al. How should patients with hepatocellular carcinoma be staged? Cancer 2000; 89: 2266–73PubMedCrossRefGoogle Scholar
  113. 113.
    Ueno S, Tanabe G, Sako K, et al. Discrimination value of the New Western Prognostic System (CLIP) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001; 34: 529–34PubMedCrossRefGoogle Scholar
  114. 114.
    Levy I, Sherman M, and the Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881–5PubMedCrossRefGoogle Scholar
  115. 115.
    Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system and the Cancer of the Liver Italian Program: a study based on 926 patients. Cancer 2002; 94: 1760–9PubMedCrossRefGoogle Scholar
  116. 116.
    Camma C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593–602PubMedCrossRefGoogle Scholar
  117. 117.
    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434–40PubMedCrossRefGoogle Scholar
  118. 118.
    Wu C-C, Ho W-L, Yeh D-C, et al. Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? Surgery 1996; 120: 34–9PubMedCrossRefGoogle Scholar
  119. 119.
    Chen M-F, Hwang T-L, Jeng L-B, et al. Postoperative recurrence of hepatocellular carcinoma. Arch Surg 1994; 129: 738–42PubMedCrossRefGoogle Scholar
  120. 120.
    Izumi R, Shimizu K, Tohru II, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106: 720–7PubMedGoogle Scholar
  121. 121.
    Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996; 131: 71–6PubMedCrossRefGoogle Scholar
  122. 122.
    Lee C-S, Sheu J-C, Wang M, et al. Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma. Br J Surg 1996; 83: 330–3PubMedCrossRefGoogle Scholar
  123. 123.
    Hannan EL. The relation between volume and outcome in health care. N Engl J Med 1999; 340: 1677–9PubMedCrossRefGoogle Scholar
  124. 124.
    Begg CB, Cramer LD, Hoskins WJ, et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747–51PubMedCrossRefGoogle Scholar
  125. 125.
    Balscils J, Charco R, Lazaro JL, et al. Resection of hepatocellular carcinoma in patients with cirrhosis. Br J Surg 1996; 83: 758–61CrossRefGoogle Scholar
  126. 126.
    Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol 1998; 29: 650–9PubMedCrossRefGoogle Scholar
  127. 127.
    Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10 year surgical experience in Japan. Gastroenterology 1996; 111:720–6PubMedCrossRefGoogle Scholar
  128. 128.
    Esumi M, Aritaka T, Arii M, et al. Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res 1986; 46: 5767–71PubMedGoogle Scholar
  129. 129.
    Sakamoto M, Hirohashi S, Tsuda H, et al. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 1989; 13: 1064–7PubMedCrossRefGoogle Scholar
  130. 130.
    Sheu J-C, Huang G-T, Chou H-C, et al. Multiple hepatocellular carcinomas at the early stage have different clonality. Gastroenterology 1993; 105: 1471–6PubMedCrossRefGoogle Scholar
  131. 131.
    Carr BI. An assay for micro-metastatic hepatocellular carcinoma [editorial]. Gastroenterology 1994; 106: 264–7PubMedGoogle Scholar
  132. 132.
    Fan S-T, Ng IOL, Poon RTP, et al. Hepatectomy for hepatocellular carcinoma. Arch Surg 1999; 134: 1124–30PubMedCrossRefGoogle Scholar
  133. 133.
    Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor. Hepatology 2000; 32: 228–32PubMedCrossRefGoogle Scholar
  134. 134.
    Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001; 134: 963–7PubMedGoogle Scholar
  135. 135.
    Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802–7PubMedCrossRefGoogle Scholar
  136. 136.
    Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353: 797–801PubMedCrossRefGoogle Scholar
  137. 137.
    Huguet C, Bona S, Nordlinger B, et al. Repeat hepatic resection for primary and metastatic carcinoma of the liver. Surg Gynecol Obstet 1990; 171: 398–402PubMedGoogle Scholar
  138. 138.
    Matsuda Y, Ito T, Oguchi Y, et al. Rationale of surgical management for recurrent hepatocellular carcinoma. Ann Surg 1993; 217: 28–34PubMedCrossRefGoogle Scholar
  139. 139.
    Shimada M, Matsumata T, Taketomi A, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 1994; 115: 703–6PubMedGoogle Scholar
  140. 140.
    Kotoh K, Sasaki H, Morotomi I, et al. The use of percutaneous ethanol injection therapy for recurrence of hepatocellular carcinoma. Hepatogastroenterology 1995; 42: 197–200PubMedGoogle Scholar
  141. 141.
    Ouchi K, Matsubara S, Fukuhara K, et al. Recurrence of hepatocellular carcinoma in the liver remnant after hepatic resection. Am J Surg 1993; 166: 270–3PubMedCrossRefGoogle Scholar
  142. 142.
    Furuta T, Kanematsu T, Matsumata T, et al. Lipiodolization prolongs survival rates in postoperative patients with a recurrent hepatocellular carcinoma. Hepatogastroenterology 1990; 37: 494–7PubMedGoogle Scholar
  143. 143.
    Welsner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD. Gastroenterology 2004; 27(5 Suppl. 1): S261–7Google Scholar
  144. 144.
    Christians KK, Pitt HA, Rilling WS, et al. Hepatocellular carcinoma: multimodality management. Surgery 2001 Oct; 130: 554–60Google Scholar
  145. 145.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–9PubMedCrossRefGoogle Scholar
  146. 146.
    Michel J, Suc B, Montpeyroux F, et al. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. J Hepatol 1997; 26: 1274–80PubMedCrossRefGoogle Scholar
  147. 147.
    Jonas S, Bechsteln WO, Stelnmuller T, et al. Vascular invasion and histologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080–6PubMedCrossRefGoogle Scholar
  148. 148.
    Figueras J, Ibanez L, Ramos E, et al. selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multi center study. Liver Transpl 2001; 7: 877–83PubMedCrossRefGoogle Scholar
  149. 149.
    Stone MJ, Klintmalm GBG, Polter D, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993; 104: 196–202PubMedGoogle Scholar
  150. 150.
    Oldhafer KJ, Chavan A, Fruhauf NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29: 953–9PubMedCrossRefGoogle Scholar
  151. 151.
    Harnois DM, Steers J, Andrews JC, et al. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl 1999; 5: 192–9CrossRefGoogle Scholar
  152. 152.
    Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311–22PubMedCrossRefGoogle Scholar
  153. 153.
    Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy [editorial]. Hepatology 2000; 31: 1019–21PubMedCrossRefGoogle Scholar
  154. 154.
    Salizzoni M, Zamboni F, Lupo F, et al. Liver transplantation for early-detected multifocal hepatocellular carcinoma. Br J Surg 2001; 88: 1194–5PubMedCrossRefGoogle Scholar
  155. 155.
    Cheng SJ, Pratt DS, Freeman RB, et al. Living-donor versus cadaveric transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 2001; 72: 861–8PubMedCrossRefGoogle Scholar
  156. 156.
    Majno PE, Sarasin FP, Mentha G, et al. Primary liver resection and salvage transplantation or primary transplantation in patients with single small hepatocellular carcinoma and preserved liver function: an outcome-orientated decision analysis. Hepatology 2000; 31: 899–906PubMedCrossRefGoogle Scholar
  157. 157.
    Sarasin FP, Majno PE, Llovet JM, et al. Liver donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073–9PubMedCrossRefGoogle Scholar
  158. 158.
    Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 1561–7PubMedCrossRefGoogle Scholar
  159. 159.
    Ohto M, Sugiura N, Ebara M, et al. Treatment of hepatocellular carcinoma by alcohol injection into the tumour and irradiation of the tumour. Gan To Kagaku Ryoho 1986; 13: 1625–34PubMedGoogle Scholar
  160. 160.
    Vilana R, Bruix J, Bru C, et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353–7PubMedCrossRefGoogle Scholar
  161. 161.
    Livraghi T, Benedini V, Lazzaroni S, et al. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer 1998; 83: 48–57PubMedCrossRefGoogle Scholar
  162. 162.
    Lencioni R, Pinto F, Armillotta N, et al. Long term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7: 514–9PubMedCrossRefGoogle Scholar
  163. 163.
    Bartolozzi C, Cioni D, Donati F, et al. Imaging evaluation of tumor response. In: Bartolozzi C, Lencioni R, editors. Liver malignancies, diagnostic and interventional radiology. 1st ed. Berlin: Springer-Verlag, 1999: 467–87Google Scholar
  164. 164.
    Sato S, Shiratori Y, Imamura M, et al. Power doppler signals after percutaneous ethanol injection therapy for hepatocellular carcinoma predict local recurrence of tumors: a prospective study using 199 consecutive patients. J Hepatol 2001; 35: 225–34PubMedCrossRefGoogle Scholar
  165. 165.
    Shiina S, Tagawa K, Unuma T, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. Cancer 1991; 68: 1524–30PubMedCrossRefGoogle Scholar
  166. 166.
    Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma. J Hepatol 1995; 22: 522–6PubMedCrossRefGoogle Scholar
  167. 167.
    Toyoda H, Kumuda T, Nakano S, et al. Significance of tumor vascularity as a predictor of long term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection therapy. J Hepatol 1997; 26: 1055–62PubMedCrossRefGoogle Scholar
  168. 168.
    Ueno H, Okada S, Okusaka T, et al. Prognosis of hepatocellular carcinoma with no tumor stain, treated by percutaneous ethanol injection. Hepatogastroenterology 2001; 48: 1430–4PubMedGoogle Scholar
  169. 169.
    Castellano L, Calandra M, Blanco C, et al. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after ethanol injection: analysis of 71 patients. J Hepatol 1997; 27: 862–70PubMedCrossRefGoogle Scholar
  170. 170.
    Khan KN, Yatsuhashi H, Yamasaki K, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32: 269–78PubMedCrossRefGoogle Scholar
  171. 171.
    Koike Y, Shiratori Y, Sato S, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216–23PubMedCrossRefGoogle Scholar
  172. 172.
    Grasso A, Watkinson AF, Tibballs JM, et al. Radiofrequency ablation in the treatment of hepatocellular carcinoma: a clinical viewpoint. J Hepatol 2000; 33: 667–72PubMedCrossRefGoogle Scholar
  173. 173.
    Rhim H, Dodd III GD. Radiofrequency thermal ablation of liver tumors. J Clin Ultrasound 1999; 27: 221–9PubMedCrossRefGoogle Scholar
  174. 174.
    Livraghi T, Goldberg NS, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655–61PubMedGoogle Scholar
  175. 175.
    Llovet JM, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124–9PubMedCrossRefGoogle Scholar
  176. 176.
    Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994; 74: 817–25PubMedCrossRefGoogle Scholar
  177. 177.
    Dong B, Liang P, Yu X, et al. Sonographically guided microwave coagulation treatment of liver cancer. AJR Am J Roentgenol 1998; 171: 449–54PubMedGoogle Scholar
  178. 178.
    Lu M, Chen J, Xie X, et al. Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy. Radiology 2001; 221: 167–72PubMedCrossRefGoogle Scholar
  179. 179.
    Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223: 331–7PubMedCrossRefGoogle Scholar
  180. 180.
    Takayasu K, Moriyama N, Muramatzu Y, et al. Hepatic arterial embolization for hepatocellular carcinoma: comparison of CT scans and resected specimens. Radiology 1984; 150: 661–5PubMedGoogle Scholar
  181. 181.
    Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992; 163: 387–94PubMedCrossRefGoogle Scholar
  182. 182.
    De Baere T, Roche A, Amenabar JM, et al. Liver abscess formation after local treatment of liver tumors. Hepatology 1996; 23: 1436–40PubMedCrossRefGoogle Scholar
  183. 183.
    Kuroda C, Iwasaki M, Tanaka T, et al. Gall bladder infarction following hepatic transcatheter-arterial embolization. Radiology 1983; 149: 85–9PubMedGoogle Scholar
  184. 184.
    Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991; 67: 385–91PubMedCrossRefGoogle Scholar
  185. 185.
    Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256–61CrossRefGoogle Scholar
  186. 186.
    Llovet JM, Real MI, Mointana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma. Lancet 2002; 359: 1734–9PubMedCrossRefGoogle Scholar
  187. 187.
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–71PubMedCrossRefGoogle Scholar
  188. 188.
    Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47–54PubMedCrossRefGoogle Scholar
  189. 189.
    Trinchet J-C, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1997; 27: 756–65PubMedCrossRefGoogle Scholar
  190. 190.
    Tanaka K, Okazaki H, Nakamura S, et al. Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1991; 179: 713–7PubMedGoogle Scholar
  191. 191.
    Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29: 129–34PubMedCrossRefGoogle Scholar
  192. 192.
    Falkson G, Maclntyre JM, Moertel CG, et al. Primary liver cancer: an Eastern Cooperative Oncology Group Trial. Cancer 1984; 54: 970–7PubMedCrossRefGoogle Scholar
  193. 193.
    Ohya T, Kikuchi S, Kato K, et al. Clinical studies of chemotherapy for primary hepatocellular carcinoma. Jpn J Cancer Chemother 1982; 54: 970–7Google Scholar
  194. 194.
    Aoki K, Okazaki N, Okada S, et al. Radiotherapy for hepatocellular carcinoma: clinicopathological study of seven autopsy cases. Hepatogastroenterology 1994; 41: 427–31PubMedGoogle Scholar
  195. 195.
    Matsuzaki Y, Osuga T, Saito Y, et al. A new, effective and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994; 106: 1032–41PubMedGoogle Scholar
  196. 196.
    Raoul JI, Bretagne JF, Caucanas JP, et al. Internal radiotherapy for hepatocellular carcinoma. Cancer 1992; 69: 346–52PubMedCrossRefGoogle Scholar
  197. 197.
    Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172: 857–60PubMedGoogle Scholar
  198. 198.
    Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994; 70: 994–9PubMedCrossRefGoogle Scholar
  199. 199.
    Friedman MA, Demanes DJ, Hoffman PG. Hepatomas: hormone receptors and therapy. Am J Med 1982; 73: 362–6PubMedCrossRefGoogle Scholar
  200. 200.
    Farinati F, De Maria N, Fornasiero A. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis sci 1992 May; 37(5): 659–62PubMedCrossRefGoogle Scholar
  201. 201.
    Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20: 702–6PubMedCrossRefGoogle Scholar
  202. 202.
    Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002; 36(5): 1221–6PubMedCrossRefGoogle Scholar
  203. 203.
    Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855–9PubMedCrossRefGoogle Scholar
  204. 204.
    Prevention of liver cancer. World Health Organ Tech Rep Ser 1983; 691: 1–30Google Scholar
  205. 205.
    Zuckerman AJ. Prevention of primary liver cancer by immunization. N Engl J Med 1997; 336: 1906–7PubMedCrossRefGoogle Scholar
  206. 206.
    Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27: 201–5PubMedCrossRefGoogle Scholar
  207. 207.
    Benvegnu L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83: 901–9PubMedCrossRefGoogle Scholar
  208. 208.
    Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C. Hepatology 1999; 29: 1124–30PubMedCrossRefGoogle Scholar
  209. 209.
    Silini E, Bottelli R, Asti M, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis; a case control study. Gastroenterology 1996; 111: 199–205PubMedCrossRefGoogle Scholar
  210. 210.
    Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha therapy. Ann Intern Med 1997; 127: 875–81PubMedGoogle Scholar
  211. 211.
    Shindo M, Hamada K, Oda Y, et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001; 33: 1299–302PubMedCrossRefGoogle Scholar
  212. 212.
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma. Ann Intern Med 1999; 131: 174–81PubMedGoogle Scholar
  213. 213.
    Collier J, Krahn M, Sherman M. A cost-benefit analysis of the benefit of screening for hepatocellular carcinoma in hepatitis B carriers [abstract]. Hepatology 1999; 30: 481AGoogle Scholar
  214. 214.
    El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139(10): 817–23PubMedGoogle Scholar
  215. 215.
    Hassan MM, Frome A, Patt YZ, et al. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35(3): 266–9PubMedCrossRefGoogle Scholar
  216. 216.
    Fattovich G, Stroffolini T, Zagni T, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5 Suppl. 1): S35–50PubMedCrossRefGoogle Scholar
  217. 217.
    Omata M, Tatelshi R, Yoshida H, et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127(5 Suppl. 1): S159–68PubMedCrossRefGoogle Scholar
  218. 218.
    Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36(1): 150–5PubMedCrossRefGoogle Scholar
  219. 219.
    El-Serag HB, Richardson PA, Everhart JE, et al. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96(8): 2462–7PubMedCrossRefGoogle Scholar
  220. 220.
    Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002; 123(1): 375–8PubMedCrossRefGoogle Scholar
  221. 221.
    Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35(6): 1485–93PubMedCrossRefGoogle Scholar
  222. 222.
    Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Gastrointest Endosc 2002; 56(4): 600–3PubMedCrossRefGoogle Scholar
  223. 223.
    Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl. 1): S97–103PubMedCrossRefGoogle Scholar
  224. 224.
    Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124(1): 114–7PubMedCrossRefGoogle Scholar
  225. 225.
    Yu MC, Yuan J-M. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl. 1): S72–8PubMedCrossRefGoogle Scholar
  226. 226.
    McGlynn KA, Hunter K, LeVoyer T, et al. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 2003; 63(15): 4594–601PubMedGoogle Scholar
  227. 227.
    Yoshida H, Tatelshi R, Arakawa Y. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425–30PubMedCrossRefGoogle Scholar
  228. 228.
    Nguyen MH, Whittemore AS, Garcia RT, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004; 2(9): 820–4PubMedCrossRefGoogle Scholar
  229. 229.
    Bruix J, Llovet JM. HCC survelllance: who is the target population? Hepatology 2003; 37(3): 507–9PubMedCrossRefGoogle Scholar
  230. 230.
    Lin OS, Keeffe EB, Sanders GD, et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19(11): 1159–72PubMedCrossRefGoogle Scholar
  231. 231.
    Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during survelllance. Gastroenterology 2004; 126(4): 1005–14PubMedCrossRefGoogle Scholar
  232. 232.
    Andriulli A, de Sio I, Solmi L, et al. Survival of cirrhotic patients with early hepatocellular carcinoma treated by percutaneous ethanol injection or liver transplantation. Liver Transpl 2004; 10(11): 1355–63PubMedCrossRefGoogle Scholar
  233. 233.
    Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10(9): 1195–202PubMedCrossRefGoogle Scholar
  234. 234.
    Yao FY, Ferrell L, Bass NM. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversciy impact survival. Hepatology 2001; 33(6): 1394–403PubMedCrossRefGoogle Scholar
  235. 235.
    Leung JY, Zhu AX, Gordon FD. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004; 10(11): 1343–54PubMedCrossRefGoogle Scholar
  236. 236.
    Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31(4): 864–71PubMedCrossRefGoogle Scholar
  237. 237.
    Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10(1): 36–41PubMedCrossRefGoogle Scholar
  238. 238.
    Sarasin FP, Majno PE, Llovet JM, et al. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33(5): 1073–9PubMedCrossRefGoogle Scholar
  239. 239.
    Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50(1): 123–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Laurie Blendis
    • 1
    • 3
  • Morris Sherman
    • 2
  1. 1.Sakler School of Medicine, Institute of Gastroenterology, Sourasky-Tel Aviv Medical CenterUniversity of Tel AvivTel AvivIsrael
  2. 2.Department of Medicine, Toronto General HospitalUniversity of TorontoTorontoCanada
  3. 3.Institute of Gastroenterology Sourasky-Tel Aviv Medical CenterTel AvivIsrael

Personalised recommendations